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Post-translational modification of proteins with ubiq-
uitin-like SUMO modifiers is a tightly regulated and
highly dynamic process. The SENP family of SUMO-
specific isopeptidases comprises six cysteine prote-
ases. They are instrumental in counterbalancing
SUMOconjugation, but their regulation is not well un-
derstood. We demonstrate that in hypoxic cell ex-
tracts, the catalytic activity of SENP family members,
in particular SENP1 and SENP3, is inhibited in a rapid
and fully reversible process. Comparative mass
spectrometry from normoxic and hypoxic cells de-
fines a subset of hypoxia-induced SUMO1 targets,
including SUMO ligases RanBP2 and PIAS2, glucose
transporter 1, and transcriptional regulators. Among
the most strongly induced targets, we identified the
transcriptional co-repressor BHLHE40, which con-
trols hypoxic gene expression programs. We pro-
vide evidence that SUMOylation of BHLHE40 is
reversed by SENP1 and contributes to transcriptional
repression of the metabolic master regulator gene
PGC-1a. We propose a pathway that connects oxy-
gen-controlled SENP activity to hypoxic reprogram-
ming of metabolism.INTRODUCTION
Members of the ubiquitin-like SUMO system function as post-
translational modifiers in all eukaryotes (Flotho and Melchior,
2013; Gareau and Lima, 2010; Wilkinson and Henley, 2010). In
human cells, three SUMO forms (SUMO1, SUMO2, and
SUMO3) can be covalently attached to lysine residues of target
proteins. Because SUMO2 and SUMO3 are highly related to
each other, they are generally treated as a single entity and
referred to as SUMO2/3. All SUMO forms are synthesized as
precursor proteins that require proteolytic processing at their
C terminus to enter the conjugation pathway. In humans, this
cleavage is catalyzed by cysteine proteases, termed SUMO-
specific isopeptidases, SUMO hydrolases, or SUMO proteasesCell Repo
This is an open access article under the CC BY-Nof the Ulp/SENP (ubiquitin-like protease/sentrin-specific prote-
ase) family or USPL1 (ubiquitin-specific peptidase-like protein 1)
(Hickey et al., 2012; Huang et al., 2015; Mukhopadhyay and
Dasso, 2007; Nayak et al., 2014; Yeh, 2009). These enzymes
clip off the terminal residues of SUMO that follow a C-terminal
diGlycine motif, whose accessibility is indispensable for the sub-
sequent activation and conjugation of SUMO. After processing,
SUMO is activated in an ATP-dependent process by the dimeric
(AOS1/UBA2) E1 activating enzyme and subsequently trans-
ferred to the E2 conjugating enzyme Ubc9. Attachment to target
proteins is finally done by Ubc9 alone or with the help of E3
SUMO ligases, such as RanBP2 or members of the PIAS family
(Flotho and Melchior, 2013; Gareau and Lima, 2010; Wilkinson
and Henley, 2010). A typical consequence of SUMO conjugation
is the alteration of protein-protein interactions (Jentsch and Psa-
khye, 2013; Raman et al., 2013). The fate of a SUMO-protein
conjugate is often related to the recognition of an interaction
partner that harbors a distinct SUMO interaction module (SIM).
Regulated deconjugation of SUMO from target proteins is a cen-
tral element of the SUMO pathway, because deconjugation gua-
rantees the plasticity of protein interaction networks. The known
mammalian SUMO-specific isopeptidases or proteases belong
to three distinct families: Ulp/SENP, Desi (deSUMOylating iso-
peptidase), and USPL1 (Hickey et al., 2012; Huang et al., 2015;
Mukhopadhyay and Dasso, 2007; Nayak et al., 2014; Yeh,
2009). The Ulp/SENP family, which is the best-characterized
group, consists of six members. Within their catalytic domains,
SENPs share 20% to 60% sequence identity. The SENP1/
SENP2, SENP3/SENP5, and SENP6/SENP7 pairs exhibit the
highest degree of similarity to each other. Distinct family mem-
bers function as deconjugating enzymes for isopeptide-linked
SUMO-protein conjugates or depolymerize isopeptide-linked
poly-SUMO2/3 chains (Nayak and M€uller, 2014). Moreover,
some family members act as processing enzymes for the C-ter-
minal maturation of the SUMO precursor.
Because of detailed structural and biochemical work, we
gained a thorough mechanistic understanding of SENP function
(Lima and Reverter, 2008; Reverter and Lima, 2004, 2006; Shen
et al., 2006a, 2006b; Xu et al., 2006). Structural data of the cata-
lytic domain uncovered the catalytic mechanism of this enzyme
class. The active site cysteine residue is embedded in a typical
catalytic triad (cysteine-histidine-aspartic acid [Cys-His-Asp])
with a conserved glutamine (Gln) residue in proximity stabilizingrts 16, 3075–3086, September 13, 2016 ª 2016 The Authors. 3075
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the transition state during catalysis. The substrate enters the cat-
alytic site through a tunnel, in which conserved tryptophan (Trp)
residues position the diglycine motif and the scissile bond over
the active site.
Despite these detailed mechanistic insights, the physiological
role of distinct SENP family members and their regulation is only
partially understood. In this work, we show that the cellular oxy-
gen supply is a critical determinant for the activity of distinct
SENP family members. Hypoxia defines a situation in which
the oxygen supply is below the physiological requirements. Hyp-
oxia occurs in various pathophysiological conditions, such as
ischemia or reperfusion injury or cancer (Semenza, 2014).
A typical consequence of hypoxia is a reduced capacity to pro-
duce energy through oxidative phosphorylation. To cope with
this problem, cells activate an adaptation mechanism, which
is primarily triggered by the hypoxia-induced transcription
factor HIF1a (Kenneth and Rocha, 2008). In normoxia HIF1a
is constantly degraded by the ubiquitin-proteasome system,
but rapidly stabilized under hypoxic conditions. This fosters the
induction of HIF1a target genes, which typically promote angio-
genesis and anaerobic ATP production through glycolysis.
Here we provide evidence that the ubiquitin-like SUMO sys-
tem contributes to the hypoxic response. In particular, we
show that the activity of the SUMO deconjugases SENP1 and
SENP3 is highly sensitive to oxygen deprivation. We propose
that this enhances SUMOylation of a subset of cellular proteins
and contributes to the adaptation of cellular metabolism to hyp-
oxic conditions.
RESULTS
Hypoxia-Induced SUMOylation Is Accompanied by
Reduced Activity of SUMO Hydrolases
Protein modification by SUMO paralogs is a highly dynamic pro-
cess. However, the signals that control the balance of SUMO
conjugation and deconjugation are not well defined. Low oxygen
was reported to enhance SUMOmodification, but the underlying
mechanism has remained unclear (Agbor et al., 2011). In addi-
tion, most studies on hypoxia-mediated control of SUMOylation
were performed in cells that stably or transiently overexpress
SUMO paralogs. To monitor whether conjugation by endoge-
nous SUMO forms is altered in response to limited oxygen sup-
ply, we incubatedHeLa cells under normoxic conditions or at 1%
oxygen for 1, 2, 4, or 24 hr. At each time point, cell extracts were
prepared under denaturing conditions and the state of SUMO
conjugation was detected by anti-SUMO1 or anti-SUMO2/3
immunoblotting (Figure 1A). To control for the cellular response
to hypoxia, HIF1a levels were followed by anti-HIF1a immuno-
blotting. As expected, hypoxia triggers strong and rapid stabili-
zation of HIF1a that is visible in the anti-HIF1a immunoblot.
SUMO conjugates are also drastically enhanced in hypoxia. In
normoxic control cells, the typical 90 kDa RanGAP1-SUMO1
conjugate can be detected in anti-SUMO1 immunoblots. In cells
kept under hypoxic conditions for 24 hr, high-molecular SUMO1
conjugates migrating above the 90 kDa RanGAP1-SUMO1 con-
jugate become detectable. This conjugation pattern is charac-
teristic for enhanced SUMO modification in different cellular
stress situations. At longer exposure, the accumulation of these3076 Cell Reports 16, 3075–3086, September 13, 2016conjugates is visible at earlier time points. Similar to what was
observed for SUMO1, SUMO2 conjugates, particularly high-
molecular-weight forms, are increased in response to hypoxia,
albeit to a lower extent. Altogether, these data support the
idea that hypoxia induces SUMOylation of cellular proteins and
in particular triggers the formation of high-molecular-weight
conjugates.
One possible explanation of hypoxia-stimulated SUMOylation
could be the induction of SUMO paralogs. However, proteome
analysis by mass spectrometry (MS) or mRNA analysis by
qRT-PCR did not reveal a significant increase in expression of
SUMO1, SUMO2, or SUMO3 (Figures S1A and S1B). Moreover,
levels of Ubc9 or PIAS family members remained unaltered
under hypoxia. We therefore hypothesized that alteration in
SUMO deconjugation may account for increased SUMOylation
in hypoxia. To follow this idea, we measured the cellular activity
of SUMO hydrolyzing enzymes in normoxic and hypoxic cells
by using a fluorescence-based activity assay. SUMO1- and
SUMO2-amidomethylcoumarine (SUMO1-AMC and SUMO2-
AMC) are sensitive fluorogenic substrates for SUMO hydrolases,
including SENP enzymes. In these reagents, AMC is linked to the
C terminus of SUMO1 or SUMO2 through an amide bond, which
is specifically hydrolyzed by SENPs (Kolli et al., 2010; Wilkinson
et al., 2005). AMC is quenched when coupled to SUMO, but
upon release it can be measured by emitted fluorescence
(Madu and Chen, 2012). SUMO1 or SUMO2-AMC probes there-
fore allow the monitoring of SENP activity in cell extracts by
following the increase in fluorescence over time. To determine
oxygen-controlled SUMO protease activity, cell extracts were
prepared from normoxic cells or from cells kept under hypoxia
for different time points and incubated with SUMO1-AMC or
SUMO2-AMC. Data from a representative experiment are shown
in Figures 1B and 1C. Generally, normoxic control cells exhibit
high cleavage activity toward SUMO2-AMC and lower activity
toward SUMO1-AMC. However, in cells kept under hypoxia,
the activity toward both SUMO1-AMC and SUMO2-AMC was
greatly reduced. For SUMO1-AMC and SUMO2-AMC, cleavage
activity was consistently reduced to 40%–50% already after
2–4 hr. After 24 hr, this was even more drastic, with SUMO1
cleavage activity reduced to 30% and SUMO2 cleavage activity
reduced to less than 20%. A reoxygenation period of 30 min was
sufficient for the full recovery of SENP activity following 4 or 24 hr
of hypoxia. Altogether, these findings support the idea that the
induction of SUMO conjugation by oxygen deprivation is linked
to reversible downregulation of SUMO protease activity.
Hypoxia Inhibits the Catalytic Activity of SENP1 and
SENP3
It has been reported that levels of SENP family members are
regulated by changes in gene expression or protein turnover
(Cimarosti et al., 2012; Guo et al., 2013; Huang et al., 2009;
Kuo et al., 2008; Yan et al., 2010). Therefore, we tested whether
the reduction of SUMO hydrolyzing activity could be linked to
altered steady-state levels of SENP family members. Immuno-
blots again revealed an increase in HIF1a, as well as SUMO
conjugation under hypoxia, but we did not detect a significant
change in the amount of SENP1, SENP2, SENP3, SENP5, and
SENP7 in cells kept under hypoxic conditions for different time
BA
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Figure 1. Hypoxia-Induced SUMOylation Is Accompanied by Reduced Activity of SUMO Hydrolases
(A) HeLa cells were cultured under normoxic conditions (5% CO2) or hypoxic conditions (1% O2) for indicated times, cells were lysed in SDS-PAGE buffer, and
proteins were separated by SDS-PAGE. After western transfer, immunoblotting was performed using anti-SUMO1, anti-SUMO2/3, anti-HIF1a, or anti-b-Tubulin
antibody. Tubulin served as a loading control.
(B) SUMO protease activity in cell extracts from normoxic, hypoxic, or hypoxic and reoxygenated HeLa cells was determined by measuring fluorescence signals
(relative light unit [RLU]) emitted from liberated AMC substrate (SUMO1-AMC) over time. As negative control, cells were treated with NEM (10 mM) to inhibit
cysteine protease activity of SUMO proteases.
(C) As in (B), using SUMO2-AMC as the substrate.points (Figure S2A). Only in the case of SENP6 did we observe a
reduced protein level after prolonged incubation under hypoxic
conditions. Altogether, this indicates that the reduced SUMO1
or SUMO2 hydrolyzing activity in hypoxic cell extracts is not pri-
marily due to reduced protein levels of SENP family members.
Based on this observation, we reasoned that hypoxia might
directly affect the catalytic activity of SENPs. To address this
point, we used hemagglutinin (HA)-tagged SUMO-vinylsulfone
(VS) derivatives, which function as active site-directed probes
for SENPs through irreversible covalent modification of their cat-alytic cysteine residue (Madu and Chen, 2012). When added to a
cell extract, active SENPs are labeled by HA-SUMO-VS and can
be detected by anti-HA antibody (Madu and Chen, 2012).
Accordingly, upon addition of HA-SUMO1-VS or HA-SUMO2-
VS to cell extracts, distinct bands at 180, 95, and 75 kDa are de-
tected (Figure S2B). Upon addition of N-ethylmaleimide (NEM),
which inactivates cysteine proteases through alkylation of their
catalytic residues, all HA-reactive bands disappear. This indi-
cates that these adducts represent noncleavable thioether
bonds of SUMO with the catalytic cysteine residues. The signalCell Reports 16, 3075–3086, September 13, 2016 3077
Figure 2. SENP1 and SENP3 Activity Is Sensitive to Hypoxia
(A) Total HeLa cell extracts prepared in SEM buffer were incubated with or without HA-SUMO1-VS or HA-SUMO2-VS as indicated for 15 min at 25C. After
separation by SDS-PAGE, immunoblots were probed with anti-SENP1 antibody. NEM was added as a negative control where indicated.
(B) As in (A), but anti-SENP3 antibody was used for detection.
(C) As in (A), but anti-SENP6 antibody was used for detection.
(D–F) HeLa cells were cultured under normoxia, hypoxia, or hypoxia and reoxygenation (24 hr hypoxia/30min reoxygenation) as indicated. Lysates were prepared
as in (A)–(C), and samples were incubated with either HA-SUMO1-VS or HA-SUMO2-VS for 15 min at 25C and blotted against SENP1 (D), SENP3 (E), or
SENP6 (F). Where indicated, NEMwas added to the sample as a negative control. In (D), the asteriskmarks an unspecific band detected by anti-SENP1 antibody.
All blots in individual sections were run on the same gel.for the prominent SUMO1-VS or SUMO2-VS adducts migrating
at 95 kDa were drastically reduced after 2 hr of hypoxia and
further diminished after 24 hr, indicating a drop of catalytic activ-
ity (Figure S2C). A 30 min period of reoxygenation after 24 hr of
hypoxia triggered the full recovery of activity, as demonstrated
by the reappearance of the 95 kDa SUMO1-VS or SUMO2-VS
adducts. In contrast to the 95 kDa signal, the 180 kDa signal
did not vanish but was reduced under hypoxia (Figure S2C). Alto-
gether, these data support the idea that hypoxia affects the
enzymatic activity of SUMO-specific isopeptidases.
To further investigate whether distinct SENP family members
are controlled by hypoxia, we first measured the activity of spe-
cific SENPs in HeLa cell extracts. To this end, extracts fromHeLa
cells, which had been incubatedwith SUMO1-VS or SUMO2-VS,
were probed with antibodies directed against distinct SENPs3078 Cell Reports 16, 3075–3086, September 13, 2016(Figures 2A–2C; Figure S3). For SENP2, SENP5, and SENP7,
we could not detect specific SUMO1-VS or SUMO2-VS adducts
due to either the lack of specific antibodies or their low activity in
HeLa cells (Figure S3). In the case of SENP1, however, a 95 kDa
SUMO1-VS or SUMO2-VS form was readily detectable upon
addition of SUMO1-VS or SUMO2-VS to cell extracts (Figure 2A).
SENP1 is equally well converted to the SUMO1-VS or SUMO2-
VS form, which is consistent with the idea that it exerts cleavage
activity toward both SUMO1 and SUMO2 conjugates. In both
cases, addition of NEM abrogated SUMO-VS adduct forma-
tion, demonstrating specificity of the reaction. Similar to what
observed for SENP1, anti-SENP3-reactive NEM-sensitive
SUMO1-VS or SUMO2-VS adductsmigrating at 95 kDawere de-
tected (Figure 2B). SENP3 is more active toward SUMO2 conju-
gates, but at least in our experimental setting, a fraction can be
converted to a SUMO1-VS conjugate. In the case of SENP6,
NEM-sensitive anti-SENP6-reactive SUMO1-VS or SUMO2-VS
adducts migrating at 180 kDa were detected (Figure 2C). Alto-
gether, these data indicate that the 95 kDa anti-HA-reactive
SUMO1-VS or SUMO2-VS conjugates visible in Figure S2B
correspond to SENP1 and SENP3, while the 180 kDa conjugate
is a SUMO1 or SUMO2-SENP6 form.
We next monitored the activity of SENP1, SENP3, and SENP6
in cells cultured for 2 or 24 hr in low oxygen (Figures 2D–2F). Un-
der these conditions, no SENP1-SUMO1-VS or SENP1-SUMO2-
VS adducts were formed, demonstrating almost complete loss
of enzymatic activity (Figure 2D). However, in extracts from cells
that had undergone 30 min of reoxygenation after 24 hr of hyp-
oxia, SENP1 activity toward both SUMO1 and SUMO2 was fully
restored. A similar scenario was observed for SENP3 activity
(Figure 2E). In normoxic cells, a fraction of SUMO1-VS is con-
verted to a SENP3 conjugate, which is consistent with its limited
activity toward SUMO1. In hypoxic cells, however, no SUMO1-
VS adducts were detectable, while a 30 min reoxygenation
period was sufficient to restore activity. The activity of SENP3 to-
ward SUMO2 was also significantly reduced in cells kept for 2 hr
in hypoxia and was almost undetectable after 24 hr. Reoxygena-
tion again fully restored activity. Altogether, these results indi-
cate that the activity of SENP1 and SENP3 is highly sensitive
to changes in oxygen concentration. In hypoxia, the activity of
both enzymes is inhibited in a rapid and fully reversible process.
When monitoring SENP6 activity, we did not observe any reduc-
tion in activity toward SUMO1 or SUMO2 in cells kept for 2 hr un-
der hypoxia (Figure 2F). At later time points (24 hr of hypoxia), we
noticed a general reduction of SENP6 levels, a phenomenon that
was even more pronounced upon reoxygenation. However,
SENP6 was still enzymatically active after 24 hr of hypoxia. Alto-
gether, this demonstrates that both SENP1 and SENP3, but not
SENP6, activity is highly sensitive to alterations in cellular oxygen
levels.
Hypoxia Alters SUMOConjugation of aDistinct Subset of
Cellular Proteins
Given that SENP1 is active toward SUMO1 and SUMO2 while
SENP3 preferentially acts on SUMO2 conjugates, we reasoned
that it is primarily the inactivation of SENP1 that triggers the
accumulation of SUMO1 conjugates in hypoxic cells. In line
with this idea, the SUMO1 conjugation pattern induced in
hypoxic cells resembles the accumulation of SUMO1 conjugates
upon small interfering RNA (siRNA)-mediated depletion of
SENP1 (Figure 3A). SENP3 depletion only minimally induced
SUMO1 conjugation, and the combination of SENP3 siRNA
and SENP1 siRNA only moderately increased SUMO1 conju-
gates when compared to depletion of SENP1 alone.
To more specifically identify the subset of cellular regulators
that exhibit enhanced conjugation to SUMO1 in hypoxia, we
followed a MS-based proteomic approach. HeLa cells were
cultured under normoxic conditions or under hypoxia for
24 hr, and endogenous SUMO1 conjugates were immunopuri-
fied under denaturing conditions according to an established
procedure (Becker et al., 2013). Immunopurified material was
released from beads by SUMO1 peptide elution, separated
by SDS-PAGE, and digested by trypsin, and peptides weremeasured by liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS), followed by relative label-free quantification
using the Max label-free quantification (LFQ) algorithm (Cox
et al., 2014). To assure accurate quantification of SUMO1 con-
jugates in normoxic and hypoxic conditions, the experiment
was performed in triplicate, and control immunoprecipitation
(IP) using mouse immunoglobulin G (IgG) was done for each
condition. Pearson correlation coefficient determination re-
vealed almost linear correlation (r > 0.9) of LFQ intensities for
the SUMO1 IP experiments in normoxic and hypoxic cells.
Moreover, principal-component analysis showed high similarity
among the triplicates (Figure S4A). The entire dataset is given in
Table S1.
In normoxia, we identified 143 SUMO1 targets that were en-
riched more than 4-fold in anti-SUMO1 immunoprecipitates
when compared to IgG controls (Figure 3B; Figure S4B). The
data show a good overlap to SUMO targets identified by Becker
et al. (2013). In hypoxic cells, we defined a set of 135 proteins as
specific SUMO1 conjugates (Figure 3C; Figure S4C). Among
these, 83 were common to normoxia (Figure 3B). Most hypoxic
SUMO substrates did not show a significant change in modifica-
tion when compared to normoxia. However, 48 proteins were at
least 2-fold more enriched in SUMO1 IPs from hypoxic cells
when compared to normoxic cells (Figure 3C). Among these,
30 exhibited at least 3-fold stronger enrichment (Figure 3C).
The E3 SUMO ligases RanBP2 and PIAS2 are found within the
group of most highly regulated proteins (>8-fold stronger
SUMOylation in hypoxia). Both RanBP2 and PIAS2 undergo
autoSUMOylation, which under normal conditions is likely
limited by SENPs. Another large subgroup of strongly enriched
SUMO targets in hypoxia (>5-fold stronger SUMOylation in hyp-
oxia) is composed of transcriptional repressors, such as FSBP,
NAB1, BHLHE40, KCTD1, KCTD15, or ETV6 (Figure 3C). Tran-
scriptional and chromatin regulators (GTF2IRD1, IRF2BP1,
CTCF, BCLAF1, ATRX, Wiz, NAP1L, or SUPT16H) are also
enriched within the group of moderately regulated hypoxia-
induced SUMO1 targets (2- to 3-fold induced in hypoxia) (Fig-
ure 3C). As discussed in detail later, some were already reported
to play a role in HIF1a signaling, raising the possibility that the
SUMO system contributes to the alterations of gene expression
programs in hypoxia. The increased hypoxic SUMOylation of the
candidates mentioned earlier is not primarily due to alteration in
protein levels, as monitored by proteomic data in normoxic and
hypoxic cell lysates (Table S1). This is different from the protea-
somal subunits PSMA6 and PSMB4/5/6, in which enhanced
SUMOylation in hypoxia correlates with elevated protein
amounts in cell extracts (Table S1). Whether this is due to induc-
tion of gene expression or SUMO-dependent changes in protein
stability remains to be determined. According to our dataset, 30
proteins exhibit at least 4-fold reduced SUMO1 conjugation in
hypoxia when compared to normoxia (Table S1). For a subset
of these candidates (13 of 30), reduced SUMOylation correlates
with an at least 2-fold reduced protein amount in hypoxic cell ex-
tracts. These candidates include RSF1 and BRD8, which were
among the most strongly downregulated SUMO1 targets in our
dataset. As discussed in detail later, both proteins were also
defined as putative downregulated SUMO3 targets in a cellular
model of ischemia (Yang et al., 2012).Cell Reports 16, 3075–3086, September 13, 2016 3079
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Figure 3. Hypoxia Triggers SUMO Conjugation to a Distinct Subset of Cellular Proteins
(A) HeLa cells were transfectedwith control siRNA or siRNA directed against SENP1, SENP3, or both, and cell lysateswere prepared in SDS-PAGE sample buffer.
Knockdown of the respective target genewas validated by immunoblotting against SENP1 or SENP3 (upper panels). The effect of siRNA-mediated knockdown of
SENP1, SENP3, or SENP1/3 on SUMO1 conjugates was monitored by immunoblotting with anti-SUMO1 antibody (lower panel).
(B) Venn diagram indicating an overlap of 83 SUMO1-target proteins quantified in each condition. In normoxia and hypoxia, 143 and 135 proteins, respectively,
were significantly enriched upon immunopurification on anti-SUMO1 beads. Proteins with a 4-fold enrichment over IgG control and a p value < 0.05 are
considered high-confidence SUMO1 targets.
(C) Volcano blot summarizing the results from quantitative MS on SUMO1 conjugates immunopurified from hypoxic cells kept for 24 hr in hypoxia. For the
identification of high-confidence SUMO1 targets, a Student’s t test comparing the LFQ intensities of the anti-SUMO1 IP and the LFQ intensity of the IgG control
was used. SUMO1 targets were visualized by plotting the difference of the log2 mean protein intensities between the SUMO1 IP and the IgG control against the
negative logarithmized p values. Proteins with 4-fold enrichment over the IgG control and a p value < 0.05 are considered high-confidence SUMO1 targets
(designated as significantly regulated). All SUMO1 targets that were at least 2-fold more enriched in SUMO1 IPs from hypoxic cells compared to normoxic cells
are colored as indicated. Proteins with a negative log2 intensity (SUMO1 IP/IgG) in normoxic cells were excluded from the analysis.Altogether, these data indicate that hypoxia alters SUMO
conjugation of a distinct subset of cellular proteins.
BHLHE40 Is a SENP-1-Regulated Hypoxic SUMO Target
Possibly Involved in Metabolic Reprogramming under
Hypoxia
Among the most strongly regulated hypoxic SUMO targets, we
identified the transcriptional co-repressor BHLHE40. Because
BHLHE40 is known to be involved in cellular adaptation to a hyp-
oxic environment, we further investigated this pathway (Kato
et al., 2014). First, we set out to validate theMS data by immuno-
blotting (Figure 4A). SUMO1 conjugates were immunopurified
from normoxic or hypoxic cell lysates under denaturing condi-3080 Cell Reports 16, 3075–3086, September 13, 2016tions, and SDS-PAGE immunoblotting was performed with
anti-BHLHE40 antibody. In both normoxic and hypoxic cell ex-
tracts, BHLHE40 can be detected around 55 kDa. However, a
SUMO1-BHLHE40 conjugate migrating at 70 kDa was only
recovered from hypoxic, not normoxic, cells (Figure 4A). In
accordance with MS data and published work, the amount of
BHLHE40 was higher under hypoxia. However, even after
longer exposure, no SUMOylated form of BHLHE40 was
detectable in normoxic cell lysates, indicating that the modi-
fication is specifically induced in hypoxia (Figure S5). To further
support these data, HeLa cells that express a single copy
of His-tagged SUMO1 under the control of a tetracycline-
inducible promoter were incubated under normoxia or hypoxia
A B
C D
(legend on next page)
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(Ullmann et al., 2012). After cell lysis, His-SUMO1 conjugates
were captured on nickel-nitrilotriacetic acid (Ni-NTA) beads.
Following SDS-PAGE, BHLHE40 and His-SUMO1 expression
was detected by anti-BHLHE40 immunoblotting (Figure 4B). In
the input samples, BHLHE40 levels were again elevated in hyp-
oxic cell extracts when compared to control. Only in hypoxic
samples was a prominent 70 kDa anti-BHLHE40-reactive form
detectable in addition to the major 55 kDa species. The amount
of this 70 kDa form was higher upon induction of His-SUMO1
expression, suggesting that it corresponds to a BHLHE40-
SUMO1 conjugate that under hypoxia is formed by endogenous
SUMO1 but can be further induced when His-SUMO1 is ex-
pressed. In agreement with this assumption, the 70 kDa species
was specifically enriched on Ni-NTA beads under hypoxic condi-
tions andwhenHis-SUMO1 expression was induced (Figure 4B).
Altogether, these data demonstrate that inhibition of SENP1 ac-
tivity in oxygen-deprived cells can trigger SUMO1 conjugation to
BHLHE40. To provide direct evidence that BHLHE40 is a target
for SENP1-catalyzed deSUMOylation in normoxic cells, we ex-
pressed FLAG-tagged wild-type BHLHE40 or a described
SUMOylation-deficient mutant in the above-mentioned His-
SUMO1 expressing cells (Hong et al., 2011; Wang et al., 2012).
Cells were either mock depleted or depleted from SENP1 by
siRNA, and after cells lysis, His-SUMO1 conjugates were
captured on Ni-NTA beads. Recovered material, as well as an
aliquot of the input, was probed by anti-FLAG antibodies (Fig-
ure 4C). In input material, a 55 kDa FLAG-BHLHE40 species
was detected in all samples. However, in SENP1-depleted cells,
an additional 70 kDa form corresponding to the His-SUMO1-
BHLHE40 conjugate was specifically enriched on Ni-NTA
beads in cells expressing wild-type BHLHE40 but not the
SUMOylation-deficient mutant (Figure 4C). These data support
the idea that BHLHE40 is a SENP1-regulated SUMO1 target,
with K159 and K279 serving as the major SUMO attachment
sites. BHLHE40 was previously described as a negative regu-
lator of PGC-1a expression (LaGory et al., 2015). To analyze
whether SUMOylation of BHLHE40 has the potential to affect
this process, we performed reporter gene assays on a luciferase
reporter that contains the promoter region of the PGC-1a gene.
In this experimental setup, the repressive potential of wild-type
BHLHE40 was higher than the repression by the SUMOylation-
deficient mutant (Figure 4D). Although the differences weremod-
erate, we found that compared to wild-type BHLHE40, we
consistently needed to double the amount of plasmid encodingFigure 4. Hypoxic SUMOylation of the Transcriptional Co-repressor BH
(A) A denaturing SUMO1 IP was performed from normoxic or hypoxic (24 hr) He
blotting against BHLHE40.
(B) Denaturing Ni-NTA pull-downwas performed in HeLa cells expressing His-SUM
and hypoxic cells were used to monitor BHLHE40 and His-SUMO1. Input (left sid
SUMO1 (lower panels). To probe for His-SUMO1 in the Ni-NTA pull-down, only on
unspecific band detected by the BHLHE40 antibody when cells are lysed in Ni-N
(C) HeLa cells were transfected with control siRNA or siRNA directed against
BHLHE40K159R,K279R was expressed. After denaturing cell lysis and Ni-NTA pull-d
His-SUMO1 (lower panel). The left panels show input samples; the right panels
cifically enriched upon Ni-NTA pull-down, while nonSUMOylated FLAG-BHLHE4
(D) Dual-luciferase reporter assay was performed on a luciferase reporter gene
plasmids. Data show the average (±SEM) from at least four independent experim
BHLHE40 or FLAG-BHLHE40K159R,K279R in a representative experiment, togethe
3082 Cell Reports 16, 3075–3086, September 13, 2016the BHLHE40 mutant to achieve comparable repression. Typi-
cally, relative luciferase activity was reduced to 40% upon trans-
fection of 200 ng of a plasmid encoding wild-type BHLHE40. To
reach this extend of inhibition, 400 ng of the plasmid encoding
BHLHE40K159,279R was required. The reduced repressive poten-
tial of the SUMO-deficient BHLHE40 variant might be due to
reduced protein stability, because immunoblotting of corre-
sponding cell extracts consistently revealed lower steady-state
levels of the mutant. Altogether, these data provide evidence
that BHLHE40 is a hypoxic SUMO target and further suggest
that SUMOylation under hypoxia may enhance its stability and
repressive potential.
DISCUSSION
Balanced SUMO conjugation and deconjugation is an important
way to control cellular signaling pathways and protein networks.
SENPs are well-established key enzymes for SUMO deconjuga-
tion. However, the physiological stimuli controlling SENP activity
are largely unknown. Here we show that hypoxia induces a rapid
and reversible inhibition of SENP1 and SENP3, thereby trig-
gering alterations in SUMO modification of a set of cellular
proteins.
The physiological consequence of enhanced SUMOylation in
hypoxia is not entirely clear, but several lines of evidence sug-
gest that the SUMO system exerts a protective function in hyp-
oxia. The strong increase in SUMO conjugation observed in
mouse models of cerebral or cardiac ischemia, as well as in
cellular models of ischemia, is mainly regarded as a tolerance
mechanism against hypoxia (Guo et al., 2013; Loftus et al.,
2009; Yang et al., 2008). Our proteomic data support the idea
that hypoxia-induced SUMOylation facilitatesmetabolic adapta-
tions in hypoxia, which are characterized by the inhibition of
mitochondrial aerobic metabolism and the activation of anaer-
obic glycolysis. The transcription factor BHLHE40 (Stra13/
DEC1) that we find hyperSUMOylated in hypoxia contributes to
the inhibitory effect of hypoxia on mitochondrial aerobic meta-
bolism through repression of genes involved in oxidative meta-
bolism (Kato et al., 2014). One key target of BHLHE40 in this
pathway is the metabolic master regulator PGC-1a (Chung
et al., 2015; LaGory et al., 2015). We show that SUMOylation
of BHLHE40 enhances its repressive potential on a PGC-1a lucif-
erase reporter gene, suggesting that its hypoxic SUMOylation
amplifies the inhibition of PGC-1a expression. It has alreadyLHE40
La cell lysates. Input and immunopurified material was analyzed by immuno-
O1 from a Tet-inducible promoter. Cell lysates (±Dox induction) from normoxic
e) and pull-down (right side) were probed for BHLHE40 (upper panels) and His-
e-tenth of the recoveredmaterial was loaded. The asterisks in the input mark an
TA lysis buffer.
SENP1, and 24 hr later, wild-type BHLHE40 or the SUMO-deficient variant
own, samples were stained against FLAG-tagged BHLHE40 (upper panels) or
show samples after pull-down. The His-SUMO1-BHLHE40 conjugate is spe-
0 is present in all samples due to its high abundance.
containing the PGC-1a promoter. Cells were transfected with the indicated
ents. The p values are given. The immunoblot shows the expression of FLAG-
r with the anti-vinculin loading control.
been reported that SUMO conjugation to BHLHE40 promotes its
ability to transcriptionally repress cyclin D1 or CLOCK/BMAL1-
mediated transcriptional activity (Hong et al., 2011; Wang
et al., 2012). The consistent, but relativelymoderate, contribution
of SUMOylation to the repressive effect of BHLHE40 observed in
reporter gene assays can be explained by SUMO-mediated tar-
geting of multiple components within transcriptional complexes
(Jentsch and Psakhye, 2013; Raman et al., 2013). SUMOylation
of PGC-1a was reported to attenuate its transcriptional activity,
and deSUMOylation of PGC-1a by SENP1 was proposed to
regulate mitochondrial biogenesis and activity (Cai et al.,
2012). We provide compelling evidence that BHLHE40 is a target
for SENP1-mediated deSUMOylation. We therefore propose
a pathway in which hypoxic inhibition of SENP1 triggers
SUMOylation of BHLHE40 and possibly other transcriptional
regulators, including PCG-1a, to counter PGC-1a induction
of mitochondrial activity. It has been proposed that SUMO
modification of BHLHE40 may either facilitate recruitment
of histone deacetylases (HDACs) or promote the stability of
BHLHE40 (Hong et al., 2011; Wang et al., 2012). Our data are
in agreement with the latter possibility, because we consistently
detect a lower steady-state level of the SUMO-deficient variant
BHLHE40K159R,K279R when compared to wild-type BHLHE40.
We are investigating the underlying mechanism.
Hypoxic SUMOylation of BHLHE40 may therefore contribute
to the inhibition of mitochondrial aerobic metabolism. Enhanced
SUMOylation of glucose transporter GLUT1 (SLC2A1) that is
found in hypoxia may in turn facilitate anaerobic glycolysis by
stimulating cellular glucose uptake, because an increase in
glucose uptake and glycolytic flux has been demonstrated
upon SUMO1 overexpression in mammalian cells (Agbor et al.,
2011). Moreover, overexpression of SENP2 reduces glucose up-
take and lactate production, supporting the critical role of the
SUMO system in reprogramming cellular glucose metabolism
(Tang et al., 2013). How the altered SUMOylation of other candi-
date targets is connected to hypoxic signaling remains to be
determined, but the enrichment of transcriptional repressors
among the hyperSUMOylated proteins points to a role for
SUMO in the coordination of hypoxic gene expression pro-
grams. Hypoxia also has been shown to redirect Ubc9 to distinct
transcription factors, thus limiting their transcriptional activity by
enhanced SUMOylation (Hsieh et al., 2013).
Our study provides a proteome-wide dataset of hypoxic
SUMOylation in mammalian cells. A comparison of our dataset
with published proteomics on altered SUMO3 conjugation
upon transient oxygen and glucose deprivation reveals some
common candidates (Yang et al., 2012). Among the 22 upregu-
lated SUMO targets identified by Yang et al. (2012), PIAS2,
IRF2BP1, and PML were found in our study. Moreover, the
related co-repressors NAB1/2 were found in both studies. In
addition, in both studies, RSF1 and BRD8 were found to be
downregulated upon hypoxia or ischemia. The limited overlap
of both studies can be explained by several facts. First, Yang
et al. (2012) used a neuroblastoma cell line stably expressing
HA-tagged SUMO3, while we enriched for proteins conjugated
to endogenous SUMO1. Second, in the work by Yang et al.
(2012), proteomics was performed upon 6 hr of oxygen and
glucose deprivation followed by 30 min of reoxygenation, whichis different from our experimental setup. Despite these differ-
ences, it will be important to investigate whether the aforemen-
tioned regulators are core factors of a common hypoxic or
ischemic SUMO response.
Ourdata support the idea that the inactivationofSENPs triggers
the accumulation of SUMO conjugates in hypoxia. Consistent
with our findings, data from SENP1 knockout mice indicate that
SENP1 is the primary activity for deSUMOylation of SUMO1-
modified proteins (Sharma et al., 2013). Although the balance of
SUMO conjugation and deconjugation in hypoxia is likely regu-
lated at multiple layers (Carbia-Nagashima et al., 2007), our data
suggest that the inactivation of SENP1 is significantly contributing
to the enrichment of SUMO1 conjugates. The subset of SUMO
targets that aredeconjugatedbySENP1hasnot yetbeendefined,
but an emerging concept is that specific SENPs counterbalance
SUMOylation of a whole set of targets that are functionally or
physically connected to one another (Jentsch and Psakhye,
2013). Notably, earlier work defined HIF1a as target for SENP1
andproposed that SENP1-mediated deSUMOylation contributes
to HIF1a stabilization in hypoxia (Cheng et al., 2007). Although we
did not detect HIF1a in our proteomic screen, the hypoxic inacti-
vation of SENP1may act as a feedbackmechanism to limit HIF1a
accumulation in prolonged hypoxia.
Only a subset of SUMO1 targets is affected in its SUMOylation
by hypoxia. RanGAP1, the key example of a target with a slow
turnover of SUMOylation, does not exhibit altered modification
in hypoxia. By contrast, the dynamic autoSUMOylation of the
E3 SUMO ligases PIAS2 and RanBP2 is highly sensitive to
SENP inhibition. While the accumulation of SUMO1 conjugates
is significant, the overall increase in SUMO2 conjugates is
limited. A possible explanation could be that SENPs, including
SENP1 and SENP3, function not only in deconjugation but also
in processing of the SUMO2/3 precursors. A reduction in their
activity therefore does not always lead to the accumulation of
conjugates and may even reduce modification due to the limited
availability of conjugatable, processed SUMO2/3. This can
explain why, in our proteomic approach, a subset of SUMO tar-
gets is not significantly enriched in hypoxia or even decreased.
Alternatively, hyperSUMOylation of some targets can lead to
proteasomal degradation by the StUbL (SUMO-targeted ubiqui-
tin ligase) pathway (Sriramachandran and Dohmen, 2014).
Considering that the StUbL pathway is triggered by SUMO
chains, we find SUMO2/3 in the SUMO1 immunoprecipitates,
indicating that we also enriched for mixed SUMO1-SUMO2/3
chains. The amount of immunopurified SUMO2 was reduced
4-fold in hypoxia compared to normoxia, which is in line with
the idea that these mixed chains are prone to proteolytic degra-
dation. Some targets with reduced hypoxic SUMOylation are
found at lower protein levels in hypoxic versus normoxic cells.
Whether this is due to SUMO-dependent turnover or transcrip-
tional repression in hypoxia remains to be determined.
The mechanistic basis for the rapid and reversible inactivation
of SENP1/3 in hypoxia is unclear, but it is tempting to speculate
that changes in the cellular redox state may act as a switch
for activation and deactivation of SENPs. One possible mecha-
nism could be the oxidation of catalytic cysteine residues by
reactive oxygen species (ROS), which is a well-established
mechanism for the reversible inactivation of deubiquitinasesCell Reports 16, 3075–3086, September 13, 2016 3083
(Cotto-Rios et al., 2012; Kulathu et al., 2013). In hypoxic cells,
ROS is mainly generated in mitochondria, but the perinuclear
clustering of mitochondria in hypoxic cells was proposed to pref-
erentially trigger the accumulation of nuclear ROS (Al-Mehdi
et al., 2012; Murphy, 2012). As primarily nuclear proteins,
SENP1 and SENP3may thus be particularly vulnerable for oxida-
tion. SENP1 is enriched at the nuclear pore and thus would be
directly exposed to perinuclear ROS. For both SENP1 and
SENP3, there is evidence that the catalytic cysteine residue un-
dergoes oxidation when cells are directly exposed to hydrogen
peroxide (Xu et al., 2008; Yang et al., 2014). Alternatively, alter-
ations in the balance between reduced (glutathione [GSH]) and
oxidized (glutathione disulfide [GSSG]) glutathione due to
hypoxic depletion of nicotinamide adenine dinucleotide phos-
phate (NADPH) could contribute to oxidative inactivation of
SENPs. In line with this idea, recent work has connected
SENP1 activity to the cellular GSSG/GSH balance (Attie, 2015;
Ferdaoussi et al., 2015).
Altogether, the oxygen-sensitive control of SENP activity
provides important insight into the regulation of this enzyme
family. Hypoxic inactivation of SENP family members may
also be important in the context of human disease, because it
may help oxygen-deprived tissues to adapt to a hypoxic
environment.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
HeLa cells were cultured under standard conditions. The cell line stably ex-
pressing His-SUMO1 from a tetracycline-inducible promoter has been
described (Ullmann et al., 2012). Hypoxic incubations were performed in a
hypoxic workstation with 1% O2, 94% N2, and 5% CO2 (Invivo2 400, Ruskinn
Technology) at 37C for the indicated times. To avoid reoxygenation of hypoxic
cells, samples were harvested within the hypoxic chamber. For siRNA knock-
down experiments, HeLa cells were transfected twice within 5 days using the
Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) ac-
cording to the manufacturer’s instructions. On day 1, cells were seeded and
reverse transfected with a total of 250 pmol of siRNA per 60 mm dish. On
day 3, the procedure was repeated. Sequences of siRNAs are listed in Supple-
mental Experimental Procedures.
SDS-PAGE, Western Blotting, and Ni-NTA Pull-Down
SDS-PAGE and western blotting was done by standard procedures. Ni-NTA
pull-down was done as previously described (Ullmann et al., 2012). Antibodies
are listed in Supplemental Experimental Procedures.
qRT-PCR and Luciferase Reporter Gene Assays
Luciferase reporter gene assays and qRT-PCR experiments were done as pre-
viously described (Nayak et al., 2014; Ullmann et al., 2012).
Measuring SUMOProtease Activity by SUMO1-AMC or SUMO2-AMC
Cleavage Assays and SUMO1-VS or SUMO2-VS Adduct Formation
SUMO protease activity in total HeLa cell lysates was determined by using
SUMO1- or SUMO2-AMC or SUMO1-VS or SUMO2-VS as substrate, as
detailed in Supplemental Experimental Procedures.
Enrichment of SUMO1 Conjugates by Immunopurification and MS
To enrich for endogenous SUMO1 targets, we followed a recently published
procedure (Barysch et al., 2014; Becker et al., 2013). For each anti-SUMO1
and IgG control IP in normoxia and hypoxia, 13 mg of protein from HeLa cell
lysates were used. Enriched SUMO1 targets and normoxic or hypoxic protein
lysates (30 mg) were subjected to in-gel digestion. Proteins were separated ac-
cording their molecular weight by subjecting them to SDS-PAGE (4%–12%3084 Cell Reports 16, 3075–3086, September 13, 2016NuPage BisTris Gel, Invitrogen) followed by Colloidal blue staining (Expedeon).
Gel lanes were cut into equal pieces and digested in the gel as described by
Shevchenko et al. (2006) and as detailed in Supplemental Experimental Pro-
cedures. Collected peptide mixtures were concentrated and desalted using
the stop and go extraction (STAGE) technique (Rappsilber et al., 2003).
Liquid Chromatography-Mass Spectrometry and Data Analysis
Details on liquid chromatography-mass spectrometry (LC-MS) and data anal-
ysis are found in Supplemental Experimental Procedures. In brief, all experi-
ments were done on a Q Exactive HF benchtop mass spectrometer (Michalski
et al., 2011). For data analysis, all acquired raw files were processed using
MaxQuant (v.1.5.3.12) (Cox and Mann, 2008) and the implemented
Andromeda search engine (Cox et al., 2011). Relative label-free quantification
of proteins was done using the MaxLFQ algorithm integrated into MaxQuant
(Cox et al., 2014).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.08.031.
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